𝔖 Bobbio Scriptorium
✦   LIBER   ✦

[128] PEGINTERFERON o-2b AND RIBAVIRIN FOR 14 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 AND RAPID VIROLOGICAL RESPONSE. THE NORTH-C TRIAL

✍ Scribed by O. Dalgard; K. Bjoro; H. Ring-Larsen; H. Verbaan

Book ID
117375230
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
82 KB
Volume
46
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pegylated interferon alfa and ribavirin
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response
✍ Olav Dalgard; Kristian BjΓΈro; Helmer Ring-Larsen; Einar Bjornsson; Mona Holberg- πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 211 KB πŸ‘ 1 views

A recent nonrandomized pilot trial showed that hepatitis C virus (HCV) patients with genotype 2/3 and rapid virological response (RVR) had a 90% sustained virological response (SVR) rate after 14 weeks of treatment. We aimed to assess this concept in a randomized controlled trial. In the trial, 428

Randomized trial of peginterferon alfa-2
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response
✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 197 KB πŸ‘ 2 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm